非诺贝特联合贝那普利治疗扩张型心肌病并发慢性心力衰竭的临床研究

陈红霞; 刘如泉; 赵丽斌

doi:10.13201/j.issn.1001-1439.2014.02.007

非诺贝特联合贝那普利治疗扩张型心肌病并发慢性心力衰竭的临床研究

- 武汉市汉口医院总院区心内科心功能室(武汉, 430012)

详细信息

通讯作者: 陈红霞,E-mail:252486826@qq.com

中图分类号: R542.2

收稿日期: 2013-09-17

修回日期: 2013-11-14

Effect of combined fenofibrate and benazepril on dilated cardiomyopathy with chronic heart failure

- Department of Cardiology, Hankou Hospital of Wuhan, Wuhan, 430012, China

More Information

Corresponding author: CHEN Hongxia, E-mail: 252486826@qq.com

Received Date: 17 September 2013

Revised Date: 14 November 2013

摘要

摘要: 目的:观察非诺贝特联合贝那普利对扩张型心肌病并发慢性心力衰竭的临床疗效。方法:将62例患者随机分成对照组和观察组, 对照组给予常规心力衰竭治疗 (地高辛、利尿剂、β受体阻滞剂) 及贝那普利, 观察组在对照组基础上加服非诺贝特。随访患者120d, 主要观察指标:NYHA分级、左心室射血分数 (LVEF)、左室舒张末期内径 (LVEDD)、三酰甘油 (TG) 及血尿酸 (BUA) 等。结果:治疗后120d, 两组NYHA分级、LVEF、LVEDD均较治疗前明显改善 (均P<0.05);与对照组相比, 观察组NYHA分级、LVEF、LVEDD及TG、BUA水平改善更明显 (均P<0.05)。结论:非诺贝特联合贝那普利能够改善扩张型心肌病并发心力衰竭的预后, 延缓慢性心力衰竭的发展。
- 扩张型心肌病 /
- 心力衰竭 /
- 非诺贝特 /
- 贝那普利
Abstract: Objective: To observe the effects of Fenofibrate and Benazepril on DCM (Dilated Cardiomyopathy) with chronic heart failure.Method: The 62patients with DCM and chronic heart failure were divided randomly into A group (control group, n=31, only treated with digitoxin, βreceptor blocker and Benazepril), and B group (test group, n=31, treated with Fenofibrate more than A group).Result: After 120days of treatment, NYHA, LVEF, LVEDD, TG and BUA are improved more significantly in the patients of B group than those of A group.Conclusion: Fenofibrate and Benazepril could improve the prognosis of the patients with DCM and chronic heart failure and delay the development of chronic heart failure.
- dilated cardiomyopathy /
- chronic heart failure /
- fenofibrate /
- benazepril

HTML全文

参考文献(12)

[1]	HUANG W Y, SUN M.The machanism of betablockade on teating the congest heart failure[J].J Clin Cardiol (China), 2002, 18:137-137.
[2]	LEUSCHNER F, PANIZZI P, CHICO-CALERO I, et al.Angiotensin-converting enzyme inhibition prevents the release of monocytes from their splenic reservoir in mice with myocardial infarction[J].Circ Res, 2010, 107:1364-1373.
[3]	FINCK B N, CHINETTI G, STAELS B.PPARs/RXRs in cardiovascular physiology and disease[J].PPAR Res, 2008, 2008:173780.doi:10.1155/2008/173780.
[4]	胡大一, 吴彦.规范心力衰竭治疗加强患者管理[J].中华心血管病杂志, 2005, 33 (6):495-497.
[5]	LEUSCHNER F, PANIZZI P, CHICO-CALERO I, et al.Angiotensin-converting enzyme inhibition prevents the release of monocytes from their splenic reservoirin mice with myocardial infarction[J].Circ Res, 2010, 107:1364-1373.
[6]	HAEMMERLE G, MOUSTAFA T, WOELKART G, et al.ATGL-mediated fat catabolism regulatescardiac mitochondrial function via PPAR-αand PGC-1[J].Nat Med, 2011, 17:1076-1085.
[7]	STAELS B, DALLONGEVILLE J, AUWERX J, et al.Mechanism of action of fenofibrate on lipid and lipoprotein metabolism[J].Circulation, 1998, 98:2088-2088.
[8]	LANDMESSER U, SPIEKERMANN S, DIKALOV S, et al.Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure:role of xanthineoxidase and extracellular superoxide dismutase[J].Circulation, 2002, 106:3073-3081.
[9]	FEHER M D, HEPBURN A L, HOGARTH M B, et al.Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuicaemia and gout[J].Rheumatology, 2003, 42:321-351.
[10]	YUAN J, WU J, HANG Z G, et al.Role of peroxisome proliferator-activated receptor A activation in acute myocardial damage induced by isoproterenol in rats[J].Chin Med J, 2008, 121:1569-1573.
[11]	YANG Y Y, LB F, WU Q, et al.Effects of fenofibrate on the myocardial energy metabolism during heart failure in the rat model of myocardial infarction[J].Chin J Hypertens, 2011, 19:129-133.
[12]	程凯, 徐珽, 唐尧, 等.非诺贝特致不良反应分析[J].华西医学, 2010, 25 (8):1536-1538.